Загрузка страницы

The biology of superagers | Nir Barzilai, MD

Lecture: The biology of superagers
Speaker: Nir Barzilai, MD
Albert Einstein College of Medicine, United States of America
Presented at: International Workshop on HIV & Aging 2017

Learn more about International Workshop on HIV & Aging 2021 that will take place from 23 September 2021 to 24 September 2021 via https://bit.ly/3tiGoJa

The integration of antiretroviral therapy (ART) into HIV care has dramatically extended the life expectancy of those living with HIV. The longer life expectancy of people with HIV infection is changing the demographics of the HIV epidemic and currently, more than half of the people living with HIV are aged 45 or older. Recent estimates in Europe suggest that more than 70% of those with HIV will be over the age of 50 by 2030, with a greater burden of co-morbidities and associated treatments. In comparison to similar HIV-negative populations, HIV-positive persons, even when on effective ART, experience an excess of morbidity and mortality. Persons on ART rarely die from complications of AIDS, but instead have an early onset of aging complications including neurocognitive decline, osteoporosis and fractures, impaired physical function, frailty, and falls. The high priority of understanding the interaction between age and HIV infection is illustrated by recent summary reports from the HIV and Aging Consensus Project in the Journal of the American Geriatrics Society and ongoing NIH Program Announcements in “Multidisciplinary Studies of HIV/AIDS and Aging”, in addition to strong voices in the community.

Registration for the webinar is open and fee is waived for healthcare professionals via this link https://bit.ly/2R1c2Of

For the Enduring Materials of the 2017 edition visit https://bit.ly/3xZGZTN

For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/

Видео The biology of superagers | Nir Barzilai, MD канала Academic Medical Education
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
26 марта 2021 г. 14:06:38
00:29:18
Другие видео канала
Preview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCPreview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDClinical Considerations of Aging People Living with HIV - Marta BoffitoClinical Considerations of Aging People Living with HIV - Marta BoffitoThe ABC of viral hepatitis | Mark Thursz, MRCPThe ABC of viral hepatitis | Mark Thursz, MRCPUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDExercise and aging | Wendy Kohrt, PhDExercise and aging | Wendy Kohrt, PhDSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchNASH and NAFLD in HIV: same or different? | Mariana Machado, MDNASH and NAFLD in HIV: same or different? | Mariana Machado, MDCase-Based Discussion of Oral Antivirals for COVID-19: Part 1  - Catia Marzolini, PharmD, PhDCase-Based Discussion of Oral Antivirals for COVID-19: Part 1 - Catia Marzolini, PharmD, PhDResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDInvitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Differentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDDifferentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDAcute hepatitis A to E, diagnosis and management | Thomas Berg, MDAcute hepatitis A to E, diagnosis and management | Thomas Berg, MDDoes resistance still matter? | Daniel Kuritzkes, MDDoes resistance still matter? | Daniel Kuritzkes, MD
Яндекс.Метрика